Evidence map›Paper›PMID 40106190›Full record

ReviewProbiotics and antimicrobial proteins2025

Lactiplantibacillus plantarum Moderating Effect on Autoimmune Celiac Disease Triggers.

Nishant Gupta, M Al-Dossari, N S Abd El-Gawaad, Saad Alghamdi, Naeem F Qusty, Ahmad O Babalghith, Virendra Kumar Yadav, Parwiz Niazi, L O Mallasiy

Abstract readReview
PubMed Publisher
In one paragraph

Review in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nishant GuptaMedical Division, River Engineering Private Limited, Ecotech-3, Greater Noida, India. micronishant@yahoo.in.
M Al-DossariMuhayil Asir, Applied College, King Khalid University, 62529, Abha, Saudi Arabia.
N S Abd El-GawaadMuhayil Asir, Applied College, King Khalid University, 62529, Abha, Saudi Arabia.
Saad AlghamdiDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
Naeem F QustyDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
Ahmad O BabalghithMedical Genetics Department, College of Medicine, Umm Al-Qura University Makkah, Makkah, Saudi Arabia.
Virendra Kumar YadavMarwadi University Research Center, Department of Microbiology, Faculty of Sciences, Marwadi University, Rajkot, 360003, Gujarat, India.
Parwiz NiaziDepartment of Biology, Faculty of Education, Kandahar University, Kandahar, 3801, Afghanistan.
L O MallasiyMuhayil Asir, Applied College, King Khalid University, 61913, Abha, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The only approved preventive treatment option GFD remains insufficient to manage Celiac Disease (CeD). A cohort of probiotic bacteria recently indicated that probiotic bacteria such as L. plantarum (LP) have a protective effect on CeD. LP has been a prominent probiotic, studied for numerous modulating properties. This review highlights and summarizes LP's ameliorating effect on various triggers/drivers of CeD. Probiotic LP potential for CeD is noticeable, mainly involving gut microbiota modulation, gluten digestion, intestinal homeostasis, CeD-associated pathogens reduction, and CD4 + T cell regulation. LP supplementation maintains intestinal physiology by improving the ratio of intestinal villus height to crypt depth. Gut microbiota modulation also improves tight junction proteins and the intestinal barrier. LP increases the digestibility of immunoreactive 33-mer gliadin peptides and regulates immune triggers such as CD4 + T cells. LP supplementation may minimize the gastrointestinal symptoms of CeD. Nevertheless, the therapeutic applicability of LP is subjected to significant clinical and nonclinical studies.

Indexed as

Celiac DiseaseLactiplantibacillus plantarumProbioticsAnimalsGastrointestinal MicrobiomeHumansGluten digestionImmune regulationImproved gut barrierIntestinal villusMicrobiota modulationProbioticProtective effectReactive oxygen speciesSuppress IL-4

Identifiers

PMID40106190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.